Formulation Development
Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen
Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise in the early stage health science field,…
ORYZON’s Ladademstat Shows Efficacy Signs in Relapsed SCLC
Oryzon Genomics, S.A. recently presented the first preliminary data from CLEPSIDRA, a Phase 2 trial investigating iadademstat in combination with standard-of-care in relapsing small cell…
ProBioGen Licenses Technology to Bayer
ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, recently announced the closing of a license agreement with Bayer AG…
Flexion Therapeutics & Xenon Pharmaceuticals Announce Acquisition
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. recently announced the companies have entered into a definitive agreement that provides Flexion with the global rights to…
Novartis Investigational Lung Cancer Therapy Granted FDA Breakthrough Therapy Designation
"We are pleased to announce that the US FDA granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET…
Nabriva Therapeutics Earns $5-Million Milestone Payment
Nabriva Therapeutics plc recently announced that Nabriva has earned a $5-million milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory…
2019 Analytical Testing in Drug Development eBook - Regulations Help Propel Testing Market
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
Catalent to Open New Clinical Supply Facility in San Diego
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, recently announced it…
Accenture Announces Collaboration With Bayer
Accenture recently announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its……
Sanofi & Abbott Partner, Changing the Way Diabetes is Managed
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes……
AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial
AC Immune SA recently announced it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of….
DURECT Earns $10-Million Milestone Payment From Gilead
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….
Pfenex Earns $11-Million Development Milestone
Pfenex Inc. recently announced it has earned an $11-million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with…….
FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement for Biotherapeutic Development
The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve….
Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center
Kaleido Biosciences, Inc. recently announced plans to develop Microbiome Metabolic Therapies (MMT) to enhance the effects of cancer immunotherapies under a new…….
Fate Therapeutics Announces FDA Clearance of IND Application
Fate Therapeutics, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for FT596, the company’s first off-the-shelf chimeric antigen…
Krystal Biotech Announces Initiation of Phase 1/2 Study
Krystal Biotech Inc. recently announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI). The study, termed…
Atossa Genetics Announces Completion of Enrollment & Dosing in Phase 1 Clinical Trial
Atossa Genetics Inc. recently announced that all participant activities have been completed in its Phase 1 clinical trial of a new proprietary modified-release oral tablet form…
Innovent & Lilly Set to Transform Diabetes Medication as Clinical Trials Begin
Innovent Biologics, Inc. recently signed a licensing agreement with Eli Lilly and Company (Lilly), one of America’s leading pharmaceutical companies, for the development and potential…
Apellis Dosed First Patient in Phase 3 Study
Apellis Pharmaceuticals Inc.recently announced the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2…
